Pathological Hallmarks of Alzheimer's Disease Antibody Sampler Kit #74113
Product Information
Kit Usage Information
Protocols
- 7074: Western Blotting
- 8243: Western Blotting, Immunoprecipitation (Agarose), Immunofluorescence
- 12885: Western Blotting, Immunoprecipitation (Agarose), Immunohistochemistry (Paraffin), Immunofluorescence
- 12990: Western Blotting, Immunofluorescence
- 14974: Western Blotting, Immunofluorescence
- 14975: Western Blotting, Immunohistochemistry (Paraffin), Immunofluorescence
- 20194: Western Blotting, Immunoprecipitation (Agarose), Immunofluorescence, Immunofluorescence
- 32098: Western Blotting, Immunofluorescence
- 46687: Western Blotting, Immunohistochemistry (Paraffin), Immunofluorescence, Immunofluorescence
- 49561: Western Blotting, Immunoprecipitation (Agarose), Immunohistochemistry (Paraffin), Immunofluorescence
Product Description
Specificity / Sensitivity
Source / Purification
Background
Amyloid β (Aβ) precursor protein (APP) is a 100-140 kDa transmembrane glycoprotein that exists as several isoforms (4). The amino acid sequence of APP contains the amyloid domain, which can be released by a two-step proteolytic cleavage (4). The extracellular deposition and accumulation of the released Aβ fragments form the main components of amyloid plaques in Alzheimer's disease (4). APP can be phosphorylated at several sites, which may affect the proteolytic processing and secretion of this protein (5-8). Aβ-43 has been suggested as a biomarker in early onset of Alzheimer's disease, where patients have lower levels of Aβ-43 in cerebrospinal fluid (8-10). Several studies have shown that Aβ toxicity of Aβ-43 is as high as Aβ-42 or Aβ-40 in different models of Alzheimer's disease, including mouse models and human disease (10).
- Johnson, G.V. and Stoothoff, W.H. (2004) J Cell Sci 117, 5721-9.
- Hanger, D.P. et al. (1998) J Neurochem 71, 2465-76.
- Bramblett, G.T. et al. (1993) Neuron 10, 1089-99.
- Mitchell, A.J. (2009) J Neurol Neurosurg Psychiatry 80, 966-75.
- Selkoe, D.J. (1996) J Biol Chem 271, 18295-8.
- Caporaso, G.L. et al. (1992) Proc Natl Acad Sci U S A 89, 3055-9.
- Hung, A.Y. and Selkoe, D.J. (1994) EMBO J 13, 534-42.
- Suzuki, T. et al. (1994) EMBO J 13, 1114-22.
- Ando, K. et al. (1999) J Neurosci 19, 4421-7.
- Iijima, K. et al. (2000) J Neurochem 75, 1085-91.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.